Epizyme, Inc. Contracts & Agreements

Consulting Agreement by and among Epizyme, Inc., BioStrategy, LLC, and Shefali Agarwal dated April 6, 2022 (Filed With SEC on August 9, 2022)

Amendment No. 1 to License Agreement between the Company and HUTCHMED Group Investment Limited (formerly known as Hutchison China MediTech Investment Limited) (Filed With SEC on August 9, 2022)

Form of Option Agreement under the 2022 Equity Incentive Plan (Filed With SEC on August 9, 2022)

Agreement and Plan of Merger, dated as of June 27, 2022, by and among the Parent, the Purchaser and the Company (Filed With SEC on June 27, 2022)

Form of Support Agreement (Filed With SEC on June 27, 2022)

Form of Contingent Value Rights Agreement (Filed With SEC on June 27, 2022)

Epizyme, Inc. 2022 Equity Incentive Plan (Filed With SEC on May 19, 2022)

Epizyme, Inc. 2013 Employee Stock Purchase Plan, as amended and effective September 1, 2022 (Filed With SEC on May 19, 2022)

Employment Offer Letter dated March 11, 2022 between the Registrant and Jerald Korn (Filed With SEC on May 10, 2022)

Executive Severance and Change in Control Plan, as amended (Filed With SEC on May 10, 2022)

Companion Diagnostics Agreement dated as of December 18, 2012 between the Registrant and Eisai Co., Ltd. on the one side and Roche Molecular Systems, Inc. on the other side (Filed With SEC on March 1, 2022)

First Amendment to the Companion Diagnostics Agreement dated October 23, 2013 between the Registrant and Eisai Co. Ltd. on the one side and Roche Molecular Systems, Inc. on the... (Filed With SEC on March 1, 2022)

Second Amendment to the Companion Diagnostics Agreement dated November 16, 2015 between the Registrant and Eisai Co. Ltd. on the one side and Roche Molecular Systems, Inc. on the... (Filed With SEC on March 1, 2022)

Consulting Agreement, dated October 1, 2021, by and between the Registrant and Victoria Vakiener (Filed With SEC on March 1, 2022)

Consulting Agreement, dated October 27, 2021, by and between the Registrant and Matthew Ros (Filed With SEC on March 1, 2022)

Underwriting Agreement, dated January 26, 2022, by and among the Company and Jefferies, LLC, as representative of the several Underwriters (Filed With SEC on January 27, 2022)

Form of Stock Option Agreement (Inducement Grant) (Filed With SEC on November 9, 2021)

Form of Restricted Stock Unit Agreement (Inducement Grant) (Filed With SEC on November 9, 2021)

Consulting Agreement dated August 4, 2021 between the Company and Robert B. Bazemore (Filed With SEC on November 9, 2021)

Employment Offer Letter dated August 4, 2021 between the Company and Grant Bogle (Filed With SEC on November 9, 2021)

License Agreement dated August 7, 2021 between the Registrant and Hutchison China MediTech Investment Limited (Filed With SEC on November 9, 2021)

Fifth Amendment to Lease dated as of August 11, 2021, by and between the Company and ARE-TECH Square, LLC (Filed With SEC on August 16, 2021)

Form of Stock Option Agreement under 2013 Stock Incentive Plan (Filed With SEC on May 6, 2021)

Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan (Filed With SEC on May 6, 2021)

Employment Offer Letter between the Company and Victoria Vakiener, dated October 23, 2018 (Filed With SEC on February 23, 2021)

Amended and Restated Collaboration and License Agreement dated as of March 12, 2015, by and between the Registrant and Eisai Co. Ltd (Filed With SEC on February 23, 2021)

Non-Employee Director Compensation Program, effective January 1, 2021 (Filed With SEC on February 23, 2021)

Amended and Restated Loan Agreement dated as of November 3, 2020 by and among the Registrant and BioPharma Credit Investments V (Master) LP, BPCR Limited Partnership and BioPharma... (Filed With SEC on February 23, 2021)

Amendment No. 2 to Collaboration Agreement dated September 17, 2020 by and between the Company and Boehringer Ingelheim International GmbH (Filed With SEC on November 6, 2020)

Employment Offer Letter between the Company and Jeffery Kutok, dated February 21, 2020 (Filed With SEC on May 4, 2020)

First Amendment to 2013 Stock Incentive Plan (Filed With SEC on May 4, 2020)

Amendment to Collaboration Agreement dated March 10, 2020 by and between the Company and Boehringer Ingelheim International GmbH (Filed With SEC on May 4, 2020)

Description of Securities of the Registrant (Filed With SEC on February 27, 2020)

Guaranty and Security Agreement dated as of November 18, 2019 by and between the Registrant and BioPharma Credit PLC (Filed With SEC on February 27, 2020)

Purchase Agreement dated as of November 4, 2019 by and between the Registrant and RPI Finance Trust (Filed With SEC on February 27, 2020)

Warrant Agreement dated as of November 4, 2019 by and between the Registrant and RPI Finance Trust (Filed With SEC on February 27, 2020)

Loan Agreement dated as of November 4, 2019 by and between the Registrant and BioPharma Credit Investments V (Master) LP and BioPharma Credit PLC (Filed With SEC on February 27, 2020)

Employment Offer Letter between the Company and Paolo Tombesi, dated July 1, 2019 (Filed With SEC on August 9, 2019)

Non-Employee Director Compensation Program (Filed With SEC on August 9, 2019)

Underwriting Agreement related to the Common Offering, dated March 6, 2019, by and among the Company and Jefferies, LLC, Citigroup Global Markets, Inc. and Cowen and Company, as... (Filed With SEC on March 7, 2019)

Underwriting Agreement related to the Preferred Offering, dated March 6, 2019, by and among the Company and Jefferies, LLC, Citigroup Global Markets, Inc. and Cowen and Company,... (Filed With SEC on March 7, 2019)

Form of Series A Preferred Stock Certificate (Filed With SEC on March 7, 2019)

Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan (Filed With SEC on February 26, 2019)

Executive Severance and Change in Control Plan (Filed With SEC on February 26, 2019)

Non-Employee Director Compensation Program (Filed With SEC on February 26, 2019)

Employment Offer Letter date June 18, 2018 by and between the Registrant and Dr. Shefali Agarwal (Filed With SEC on November 2, 2018)

Underwriting Agreement, dated October 2, 2018, by and between the Company and Jefferies, LLC (Filed With SEC on October 3, 2018)

Third Amendment to the Companion Diagnostics Agreement dated March 7, 2018 between the Registrant and Eisai Co. Ltd. on the one side and Roche Molecular Systems, Inc. on the other... (Filed With SEC on May 8, 2018)

Underwriting Agreement, dated September 13, 2017, by and among the Company and Morgan Stanley & Co. LLC, Jefferies, LLC and Leerink Partners LLC, as representatives of the several... (Filed With SEC on September 14, 2017)

THIRD AMENDMENT TO LEASE (Filed With SEC on May 30, 2017)

FOURTH AMENDMENT TO LEASE (Filed With SEC on May 30, 2017)

SECOND AMENDMENT TO LEASE (Filed With SEC on August 8, 2016)

EPIZYME, INC. Non-Employee Director Compensation Program (Filed With SEC on May 9, 2016)

- 2 - (Filed With SEC on May 6, 2016)

EPIZYME, INC. ExecutiveSeverance and Change in Control Plan (as amended February 25, 2016) (Filed With SEC on March 9, 2016)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on March 9, 2016)

Epizyme, Inc. 13,333,334 Shares Common Stock ($0.0001 parvalue) Underwriting Agreement (Filed With SEC on January 7, 2016)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on August 6, 2015)

CONSULTING AGREEMENT (Filed With SEC on August 6, 2015)

Epizyme, Inc. 6,000,000 Shares Common Stock ($0.0001 parvalue) Underwriting Agreement (Filed With SEC on March 18, 2015)

AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT by and between EISAICO., LTD. and EPIZYME, INC. (Filed With SEC on March 16, 2015)

EPIZYME, INC. RESTRICTED STOCKUNIT AGREEMENT (Filed With SEC on March 12, 2015)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on March 12, 2015)

FIRST AMENDMENT TO THE CONSULTING AGREEMENT (Filed With SEC on March 12, 2015)

- 2 - (Filed With SEC on February 3, 2015)

- 2 - (Filed With SEC on November 6, 2014)

CONSULTING AGREEMENT (Filed With SEC on October 27, 2014)

CONSULTING AGREEMENT (Filed With SEC on September 2, 2014)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisk denote omissions. Amendment to Collaboration and License Agreement (Filed With SEC on May 14, 2014)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on April 22, 2014)

Epizyme, Inc. Shares Common Stock ($0.0001 par value) Underwriting Agreement (Filed With SEC on February 3, 2014)

Confidential Materials omitted and filed separately with the Securities andExchange Commission. Double asterisks denote omissions. Amendment to Collaboration and License Agreement (Filed With SEC on January 28, 2014)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. FIRST AMENDMENT TO COMPANION DIAGNOSTICS... (Filed With SEC on January 27, 2014)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on January 27, 2014)

FIRST AMENDMENT TO LEASE (Filed With SEC on October 23, 2013)

Epizyme, Inc. Shares 1 Common Stock ($0.0001 par value) Underwriting Agreement (Filed With SEC on May 13, 2013)

COLLABORATION AND LICENSE AGREEMENT by and between GLAXO GROUP LIMITED and EPIZYME, INC. (Filed With SEC on May 13, 2013)

COLLABORATION AND LICENSE AGREEMENT by and between EISAI CO., LTD. and EPIZYME, INC. (Filed With SEC on May 13, 2013)

COLLABORATION AND LICENSE AGREEMENT among CELGENE INTERNATIONAL SÀRL, CELGENE CORPORATION and EPIZYME, INC. (Filed With SEC on May 13, 2013)

Confidential Materials omitted and filed separately with the Securities andExchange Commission. Double asterisks denote omissions. (Filed With SEC on May 13, 2013)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on May 13, 2013)

EPIZYME, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (Filed With SEC on May 13, 2013)

Signature(s) Guaranteed: Medallion Guarantee Stamp (Filed With SEC on April 26, 2013)

EPIZYME, INC. 2013 STOCK INCENTIVE PLAN (Filed With SEC on April 26, 2013)

EPIZYME, INC. Incentive Stock Option Agreement Granted Under 2013 Stock Incentive Plan (Filed With SEC on April 26, 2013)

EPIZYME, INC. Nonstatutory Stock Option Agreement Granted Under 2013 Stock Incentive Plan (Filed With SEC on April 26, 2013)

EPIZYME, INC. Restricted Stock Agreement (Filed With SEC on April 26, 2013)

EPIZYME, INC. 2013 EMPLOYEE STOCK PURCHASE PLAN April 18, 2013 (Filed With SEC on April 26, 2013)

EPIZYME, INC. Executive Severance and Change in Control Plan (Filed With SEC on April 26, 2013)

[Company Letterhead] (Filed With SEC on April 26, 2013)

INDEMNIFICATION AGREEMENT (Filed With SEC on April 26, 2013)

EPIZYME, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT April 2, 2012 TABLE OF CONTENTS (Filed With SEC on April 18, 2013)

EpiZyme, Inc. 2008 STOCK INCENTIVE PLAN (Filed With SEC on April 18, 2013)

Epizyme, Inc. Incentive Stock Option Agreement Granted Under 2008 Stock Incentive Plan (Filed With SEC on April 18, 2013)

Epizyme, Inc. Nonstatutory Stock Option Agreement Granted Under 2008 Stock Incentive Plan (Filed With SEC on April 18, 2013)

EpiZyme, Inc. Restricted Stock Agreement Granted Under 2008 Stock Incentive Plan (Filed With SEC on April 18, 2013)

COLLABORATION AND LICENSE AGREEMENT by and between GLAXO GROUP LIMITED and EPIZYME, INC. (Filed With SEC on April 18, 2013)

COLLABORATION AND LICENSE AGREEMENT by and between EISAI CO., LTD. and EPIZYME, INC. (Filed With SEC on April 18, 2013)

COLLABORATION AND LICENSE AGREEMENT among CELGENE INTERNATIONAL SÀRL, CELGENE CORPORATION and EPIZYME, INC. (Filed With SEC on April 18, 2013)

Confidential Materials omitted and filed separately with the Securities andExchange Commission. Double asterisks denote omissions. (Filed With SEC on April 18, 2013)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on April 18, 2013)

LEASE by and between BMR-325 VASSAR STREET LLC, a Delaware limited liability company and EPIZYME, INC., a Delaware corporation LEASE (Filed With SEC on April 18, 2013)

LEASE AGREEMENT (Filed With SEC on April 18, 2013)

Category

Industry

Companies

Contracts

Epizyme, Inc. Contracts & Agreements